Gyre Therapeutics (GYRE) announced that the Center for Drug Evaluation of China’s National Medical Products Administration, or NMPA, has granted priority review status to the New Drug Application for Hydronidone as a treatment for chronic hepatitis B-induced liver fibrosis, which is liver damage resulting from the infection of the hepatitis B virus. Gyre, through its majority-owned subsidiary, Gyre Pharmaceuticals Co., plans to submit a formal NDA in the near future.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GYRE:
- Gyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions
- Gyre Therapeutics Projects Strong Growth for Fibrosis Programs
- Gyre Therapeutics reports Q4 EPS (2c), consensus 1c
- Gyre Therapeutics sees FY26 revenue $100.5M-$111M, consensus $148M
- Gyre Therapeutics to Acquire Cullgen in All-Stock Merger